417 related articles for article (PubMed ID: 26268434)
1. Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.
Zheng YQ; Naguib YW; Dong Y; Shi YC; Bou S; Cui Z
Expert Rev Vaccines; 2015; 14(9):1255-75. PubMed ID: 26268434
[TBL] [Abstract][Full Text] [Related]
2. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour research of recombinant BCG using BZLF1 and hGM-CSF fusion genes.
Xue QJ; Li YQ; Yang CQ; Chen T; Li XZ; Cheng B; Wang CM
Vaccine; 2017 Mar; 35(12):1599-1607. PubMed ID: 28228322
[TBL] [Abstract][Full Text] [Related]
4. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
[TBL] [Abstract][Full Text] [Related]
5. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.
Luo Y; Henning J; O'Donnell MA
Clin Dev Immunol; 2011; 2011():728930. PubMed ID: 21941579
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Mycobacterium bovis BCG.
Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
[TBL] [Abstract][Full Text] [Related]
7. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
8. Recombinant BCG vaccine candidates.
Hernàndez-Pando R; Castañòn M; Espitia C; Lopez-Vidal Y
Curr Mol Med; 2007 Jun; 7(4):365-72. PubMed ID: 17584076
[TBL] [Abstract][Full Text] [Related]
9. Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.
Hart BE; Hale LP; Lee S
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004046. PubMed ID: 26393347
[TBL] [Abstract][Full Text] [Related]
10. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
11. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
Im EJ; Saubi N; Virgili G; Sander C; Teoh D; Gatell JM; McShane H; Joseph J; Hanke T
J Virol; 2007 Sep; 81(17):9408-18. PubMed ID: 17596303
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.
Aldovini A; Young RA
Nature; 1991 Jun; 351(6326):479-82. PubMed ID: 2046750
[TBL] [Abstract][Full Text] [Related]
13. Manipulation of BCG vaccine: a double-edged sword.
Singh VK; Srivastava R; Srivastava BS
Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):535-43. PubMed ID: 26810060
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.
Sixsmith JD; Panas MW; Lee S; Gillard GO; White K; Lifton MA; Balachandran H; Mach L; Miller JP; Lavine C; DeMarco CT; Tomaras GD; Gee C; Porcelli SA; Larsen MH; Frothingham R; Schmitz JE; Jacobs WR; Haynes BF; Letvin NL; Korioth-Schmitz B
Clin Vaccine Immunol; 2014 Oct; 21(10):1385-95. PubMed ID: 25080550
[TBL] [Abstract][Full Text] [Related]
16. A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.
Tullius MV; Harth G; Maslesa-Galic S; Dillon BJ; Horwitz MA
Infect Immun; 2008 Nov; 76(11):5200-14. PubMed ID: 18725418
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
Deng YH; He HY; Zhang FJ
Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
[TBL] [Abstract][Full Text] [Related]
18. The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview.
Mouhoub E; Domenech P; Ndao M; Reed MB
Front Microbiol; 2021; 12():757858. PubMed ID: 34745066
[TBL] [Abstract][Full Text] [Related]
19. Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates.
Méndez-Samperio P
Scand J Immunol; 2019 Oct; 90(4):e12772. PubMed ID: 31055842
[TBL] [Abstract][Full Text] [Related]
20. Recombinant live vaccine candidates against tuberculosis.
Kaufmann SH; Gengenbacher M
Curr Opin Biotechnol; 2012 Dec; 23(6):900-7. PubMed ID: 22483201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
